Year: 2013
Type: article
Abstract: A signal of cardiovascular harm with rosiglitazone led to a new FDA policy on diabetes-drug approval. As that signal has faded in recent analyses, should FDA policy change?
Source: New England Journal of Medicine
DOI: 10.1056/nejmp1309610
Authors: William R. Hiatt, Sanjay Kaul, Robert J. Smith
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2329117883
